Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate
Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate
Verge's AI-enabled CONVERGE platform identified and validated the targets, with 83% of prioritized targets validated in disease-relevant models.On Wednesday, Verge Genomics announced that Eli Lilly And Co (NYSE:LLY) has opted to pursue the development of therapeutics against two validated drug targets for amyotrophic lateral sclerosis (ALS) as part of the companies' collaboration, which was initiated in July 2021.
在週三，Verge Genomics宣佈，禮來（紐交所：LLY）選擇繼續開發針對運動神經元病（ALS）兩個已驗證藥物靶點的治療方法，這一合作始於2021年7月。
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a nervous system disease that affects the nerve cells in the brain and spinal cord.
運動神經元病（ALS），也稱爲盧·蓋裏希病，是一種影響大腦和脊髓神經細胞的神經系統疾病。
Also Read: Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%
另請閱讀：禮來的研究藥物將粘性膽固醇水平降低了近86%。
Verge's AI-enabled CONVERGE platform identified and validated the targets, with 83% of prioritized targets validated in disease-relevant models.
Verge的人工智能驅動的CONVERGE平台識別並驗證了這些靶點，83%的優先靶點在與疾病相關的模型中得到了驗證。
Target selection triggered near-term milestone payments from Lilly to Verge. As the programs progress, Verge is eligible for additional downstream economics.
靶點選擇觸發了禮來對Verge的短期里程碑支付。隨着項目的推進，Verge有資格獲得額外的下游收益。
In 2021, Verge and Lilly entered a three-year collaboration to discover and validate novel therapeutic targets for ALS that would become the focus for subsequent drug discovery and development.
在2021年，Verge和禮來達成了爲期三年的合作，以發現和驗證用於ALS的新型治療靶點，這將成爲後續藥物發現和開發的重點。
Verge received up to $25 million in upfront equity investment and potential near-term milestones, with a total deal value of $694 million plus potential downstream royalties.
Verge獲得了最高達2500萬美元的前期股權投資和潛在的短期里程碑，總交易價值爲69400萬美元，加上潛在的下游版稅。
Verge also continues to advance VRG50635, its internal lead drug candidate for sporadic and familial ALS.
Verge還在推進其內部領先藥物候選VRG50635，用於散發性和家族性ALS。
VRG50635 is currently being evaluated in a Phase 1B Proof-of-Concept (PoC) study in Canada and several European countries. Enrollment is complete and dose escalation, including to the highest dose level, is ongoing.
VRG50635目前正在加拿大和多個歐洲國家進行第10億階段的概念板塊（PoC）研究。招募已完成，劑量遞增，包括最高劑量的遞增，仍在進行中。
Price Action: Eli Lilly stock is up 2.75% at about $749 at the last check Wednesday.
價格動態：禮來股票在週三最後一次檢查時上漲2.75%，約爲749美元。
- Global-E Soars: Q3 Sales Surge 32%, FY24 Outlook Raised Amid GMV Boom
- 全球貨幣-E飆升：第三季度銷售激增32%，全年展望在GMV激增中上調
譯文內容由第三人軟體翻譯。
